Project Title: Detrimental effect of anti-PD-1 antibody treatment on tumor growth: role of innate immune and stromal cells?
We are seeking to recruit a post-doctoral fellow to conduct a project on Tumor Immunology/Immunotherapy at the Department of Biomedical Sciences for Health/Fondazione IRCCS – Istituto Nazionale dei Tumori Molecular Targets Unit in Milan. We are looking for a highly motivated researcher to join our group.
Topic of the research: Programmed Death-1 (PD-1), a member of the CD28 receptor family, is reported to be expressed by activated T lymphocytes. This receptor is known to inhibit T cell activity upon its interaction with its ligands, PD-L1 and -L2. The PD-1/PD-Ls pathway is a crucial self-tolerance pathway that tumor cells hijack to escape immune elimination. Drugs designed to block PD-1 “release the brakes” on anti-tumor immunity, enabling endogenous effector mechanisms. Clinical studies with antibodies targeting PD-1 demonstrated that blocking the PD-1/PD-Ls interaction produced objective responses in a wide spectrum of solid and hematologic malignancies. However, it is now emerging that a fraction of patients become “hyperprogressors” after PD-1 blocking therapy with a greatly accelerated rate of tumor growth and clinical deterioration. The cellular and molecular mechanisms of this phenomenon have not been elucidated yet. The research goal is dedicated to the investigation of the molecular and cellular bases of this phenomenon.
Duration of fellowship: 3 years (renewal each year)
Candidate requirements include Ph.D, a high degree of motivation in academic research and a good ability to work independently. Skills in cellular and molecular biology/immunology are required. Experience with mouse preclinical models is desirable.
Please send a CV to Dr. Michele Sommariva at the following email address: email@example.com